LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Open

3.43 -2.28

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.38

Max

3.46

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
EPS	-0.712
Winstmarge	-77.289
Werknemers	260
EBITDA	4M -8.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+23.91% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-17M 104M
Vorige openingsprijs	5.71
Vorige sluitingsprijs	3.43

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 dec 2025, 23:54 UTC

Belangrijke Marktbewegers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec 2025, 19:08 UTC

Acquisities, Fusies, Overnames

Correction to Alphabet to Buy Intersect Article

22 dec 2025, 17:21 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec 2025, 23:42 UTC

Marktinformatie

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec 2025, 22:30 UTC

Winsten

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 21:37 UTC

Acquisities, Fusies, Overnames

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec 2025, 20:52 UTC

Acquisities, Fusies, Overnames

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec 2025, 20:09 UTC

Marktinformatie

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec 2025, 19:56 UTC

Marktinformatie

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec 2025, 19:49 UTC

Acquisities, Fusies, Overnames

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec 2025, 19:23 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec 2025, 19:23 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Precious Metals Climb to New Heights -- Market Talk

22 dec 2025, 18:45 UTC

Marktinformatie

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec 2025, 18:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec 2025, 18:23 UTC

Acquisities, Fusies, Overnames

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 dec 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

23.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.25 USD 23.91%

Hoogste 5.5 USD

Laagste 3 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.